Mutares Shareholders Face Final Call Amid Debt and Dilution Pressures

Mutares SE's rights issue ends April 21. Funds target US expansion and covenant relief as the firm posts record 2025 results ahead of key shareholder dates.

Time is running out for shareholders of German investment firm Mutares SE. The subscription period for its ongoing capital increase closes this Thursday, April 21, leaving investors with a stark choice: pay up or miss out. The rights issue, which offers one new share for every five held at a price of €24.50, carries no compensation for unexercised rights. With the stock trading at €25.25—hovering just above its new 52-week low of €25.15—the decision is fraught. The share price has fallen nearly 16 percent since the start of the year.

The capital raise aims to secure gross proceeds of up to €105 million through the issuance of roughly 4.27 million new shares, representing about 20 percent of the existing share capital. While retail investors deliberate, institutional demand has been robust. The institutional tranche, which raised €26.4 million, was nearly three times oversubscribed, with over 60 percent of orders originating from the United States and United Kingdom.

A primary driver for the cash call is an aggressive expansion into the US market. Approximately 80 percent of the net proceeds are earmarked for this push, which includes establishing a second office alongside its existing Chicago base to manage a transaction pipeline valued at €4.8 billion in revenue.

The remaining funds are urgently needed to shore up the balance sheet. The company has acknowledged it will breach a covenant linked to its net debt-to-equity ratio for its 2023/2027 and 2024/2029 bonds. Management has requested a waiver from bondholders until June 29, 2026. To address the overhang, Mutares plans to buy back at least €25 million of its 2023/2027 bond per quarter starting in the second quarter of this year.

This financial maneuvering unfolds against a backdrop of strong operational performance. Based on preliminary figures, 2025 was a record year. The holding company's net income climbed to €130.4 million, while group revenue reached €6.5 billion. For 2026, management is targeting revenue between €7.9 billion and €9.1 billion and net income in a range of €165 million to €200 million.

The coming weeks are packed with critical events that will shape the investment case. On April 28, the new shares from the capital increase will be delivered, and the company will publish its audited annual report for 2025. This will be followed by first-quarter 2026 results on May 12. The deadline for bondholders to grant the covenant waiver is June 29.

Simultaneously, Mutares continues to actively rotate its portfolio. The sale of Kalzip on April 8 marked its third exit in quick succession. Three further exits are poised for signing, with four portfolio closings scheduled for the second quarter of 2026.

April 28 thus emerges as a pivotal date, concentrating multiple catalysts into a single session. Investors will receive audited financials, see the dilutive impact of new shares, and gain early insight into the likelihood of securing crucial bondholder consent. For shareholders navigating this complex landscape, the immediate deadline is clear, but the path beyond remains tightly scheduled.